Oseltamivir Safe For Pregnant Women?

Oseltamivir, also known as Tamiflu, is a neuraminidase inhibitor used to treat and prevent influenza. The US Centers for Disease Control and Prevention (CDC) recommends that pregnant women with suspected or confirmed influenza receive prompt antiviral therapy with oseltamivir. While oseltamivir is categorised as a Pregnancy Category C drug, indicating a lack of studies in pregnant women, the CDC believes that the benefits of antiviral therapy outweigh the potential risks. Animal studies have shown that the drug crosses the placenta, but post-marketing reports and observational studies in humans have shown no evidence of malformations or fetal/neonatal toxicity.

Oseltamivir is safe to use in pregnancy

Oseltamivir has been demonstrated to prevent disease among exposed individuals, as well as to shorten the duration of illness and lessen the likelihood of complications among those infected. The safety data that are available, in addition to growing clinical experience, provide evidence for its use in pregnancy. Published prospective and retrospective observational studies of about 1500 women exposed to this drug during pregnancy (including about 400 exposed in the first trimester) indicate no increase in the observed rate of congenital malformations above the general comparison population, regardless of when exposure occurred during the gestation period.

However, it is important to note that Oseltamivir is categorised as "Pregnancy Category C" in the US, which means that it has not been studied in pregnant women. Nevertheless, this categorisation does not mean that the drug cannot be used in pregnant women. Pregnant women can and should receive a category C drug when the possible benefits of using the drug are more likely than the possible risk of harm to the woman or her baby.

The benefits of oseltamivir outweigh the risks

Influenza infection during pregnancy, especially in the first trimester, is associated with a heightened risk of adverse outcomes, including a 2.0-fold increased risk of any major malformation, a 3.3-fold increased risk of neural tube defects, and a 1.6-fold increased risk of congenital heart defects. The risks of influenza for pregnant women are serious, and the CDC believes that the benefits of antiviral therapy outweigh the potential risks from the drugs.

Oseltamivir (Tamiflu®) is the first-line recommended and most commonly used pharmaceutical agent for influenza prophylaxis and treatment. It has been demonstrated to prevent disease among exposed individuals, as well as to shorten the duration of illness and lessen the likelihood of complications among those infected. The drug has been shown to reduce rates of infection by 70-90% when used once daily as directed.

While there are no controlled data in human pregnancy, data from post-marketing reports and observational studies (over 1000 exposed outcomes during the first trimester) have shown no malformative or fetal/neonatal toxicity by this drug. Published prospective and retrospective observational studies of about 1500 women exposed to this drug during pregnancy (including about 400 exposed in the first trimester) indicate no increase in the observed rate of congenital malformations above the general comparison population, regardless of when exposure occurred during the gestation period.

Therefore, the benefits of oseltamivir outweigh the risks, especially considering the serious risks of influenza for pregnant women and the lack of evidence of harm associated with oseltamivir treatment.

Oseltamivir is not teratogenic

Oseltamivir is deemed safe for use in pregnancy and is currently the first-line recommended and most commonly used pharmaceutical agent for influenza prophylaxis and treatment. The medication has been shown to prevent disease among exposed individuals, as well as shorten the duration of illness and lessen the likelihood of complications among those infected.

The Centers for Disease Control and Prevention (CDC) recommends that pregnant women in any trimester with a suspected or confirmed influenza infection receive prompt antiviral therapy with oseltamivir (Tamiflu) or Relenza (zanamivir). Both drugs are designated "Pregnancy Category C," meaning they have not been studied in pregnant women. However, this categorization does not mean the drugs cannot be used in pregnant women. In fact, the CDC believes that the benefits of antiviral therapy outweigh the potential risks from the drugs.

The safety data available for oseltamivir, along with growing clinical experience, provide evidence for its use in pregnancy. Importantly, oseltamivir has been shown to reduce the duration of infection and hasten recovery among adults and children with influenza. Additional systematic review data suggest that the medication may also reduce the chances of severe illness and hospitalization among infected individuals.

Oseltamivir is an important drug for use in pregnancy given the increased risks associated with influenza infection during this time. While the medication is considered safe, it is always recommended to consult a doctor or medical professional for personalized advice.

Oseltamivir crosses the placenta

Oseltamivir, also known by its brand name Tamiflu, is an antiviral medication used to treat influenza. It is generally considered safe for use during pregnancy when the benefits to the mother outweigh the potential risks to the fetus. While animal studies have shown that oseltamivir crosses the placenta, there is limited data on its use in human pregnancy.

According to the US Centers for Disease Control and Prevention (CDC), oseltamivir is the preferred treatment for pregnant women with suspected or confirmed influenza. This is because pregnant women are at an increased risk of severe complications from influenza, which can lead to adverse pregnancy and fetal outcomes. The CDC recommends prompt antiviral therapy for pregnant women in any trimester with suspected or confirmed influenza.

While oseltamivir has been classified as a "Pregnancy Category C" drug by the US Food and Drug Administration (FDA), indicating a lack of studies in pregnant women, this does not mean it cannot be used during pregnancy. In fact, pregnant women can and should receive Category C drugs when the potential benefits outweigh the potential risks.

Observational studies and post-marketing reports involving over 1,000 exposed outcomes during the first trimester of pregnancy have shown no evidence of malformations or fetal/neonatal toxicity associated with oseltamivir. Additionally, published studies of approximately 1,500 women exposed to the drug during pregnancy indicate no increase in the rate of congenital malformations compared to the general population. However, individual studies had small sample sizes and lacked dosing information, preventing a definitive assessment of risk.

Animal studies have shown that oseltamivir crosses the placenta, but there is limited data on its transfer to the fetus in human pregnancies. Ex vivo placental models have suggested minimal or low transplacental transfer of oseltamivir and its active metabolite, oseltamivir carboxylate, at normal therapeutic drug levels. However, a case report of a critically ill pregnant woman treated with oseltamivir found significant levels of the drug in cord blood, indicating that it can cross the placenta at higher doses.

In summary, while oseltamivir is generally considered safe for use during pregnancy when the benefits outweigh the risks, more research is needed to fully understand its placental transfer and potential effects on the fetus. The limited data available suggest that oseltamivir can be used without adverse pregnancy or fetal outcomes, but it is recommended that it be reserved for critically ill pregnant women due to the unknown impact of drug exposure on the fetus.

Oseltamivir is safe for breastfeeding

According to a study, low levels in milk resulting in a subtherapeutic dose to the infant, pathogenicity of the circulating influenza virus strain, and the underlying maternal condition should also be considered. The study also found that the maximum relative infant dose was estimated to be 0.012 mg/kg/day, or about 0.5% of the mother's weight-adjusted dose (assuming a body weight of 60 kg). This indicates that the drug level in breast milk is clinically insignificant.

The US CDC recommended that women infected with the 2009 H1N1 influenza virus continue breastfeeding, regardless of whether they were being treated, due to the advantages of breast milk for the infant's immune system.

Frequently asked questions